The reading desk.

PCAC backed 6 of 7 peptides in July. On 28 Oct HHS filed an interim compounding policy for all six. It is not a rule and does not cover research vials.

HHS says it will not act against 503A pharmacies compounding BPC-157, TB-500, epitalon, KPV, MOTS-c or semax under ten conditions. Research vials are not covered.

Kovera Labs is a US peptide testing lab listing an Illinois address. What 1,816 of its COAs show, vendor by vendor: who passes, who fails and how to check.

32 public thymosin alpha-1 lab results: median fill 113.2% of label, purity 99.70%, no fails. Plus FDA's 17-to-4 advisory vote against compounding it.

Eli Lilly sued American Peptides LLC in Louisiana federal court on 8 Oct 2026. The complaint isn't public. Which site, the 100/100 rating, what's next.

Lilly has filed 11 retatrutide suits since August 2026; three have ended and eight are open. Lilly says Texas Peptides settled. The dockets and evidence.

A trial doctor told Women's Health grey-market reta often lacks active ingredient. 319 of 322 published identity tests disagree; Finnrick shows 16% fail.

FDA sent five peptide warning letters dated 24 Aug 2026; Lilly sued six retatrutide sellers on 12 Aug. Code names, bac water and calculators were evidence.

Five FDA warning letters dated 2026-08-24, six Lilly retatrutide suits on 2026-08-12, the Empower letter on 2026-09-18. A dated chronology.

Freedom Diagnostics signs more vendor COAs than any lab in PepIndex's index, and its lookup works. No ISO 17025 accreditation found. How to check a report.

Peptide prices on 21 October 2026: retatrutide $6.50/mg, BPC-157 $6.12, TB-500 $7.03, GHK-Cu $0.79. Medians from 128 listings at 9 vendors, and the gaps.

FDA has sent 22 warning letters citing retatrutide since Dec 2024. On 10 Oct 2026, six of the named sites still listed it with a cart button.

Is Glacier Aminos legit? 78 Kovera Labs reports: median fill 110.2% of label, median purity 99.92%, 3 fails. Plus two similar-name domains in search.

Yes, as a lab. Janoshik is an independent Czech lab whose reports verify on its own servers. What 337 public reports show, and what a pass does not prove.

Two FDA death reports name products sold as retatrutide, per CBS News, and poison center exposures rose from 249 to 862 a quarter. What they can show.

Between February and April 2026 one sponsor registered eight trials for BPC-157, TB-500, GHK-Cu, MOTS-c, Melanotan II, tesamorelin, tirzepatide and retatrutide. One record calls itself fictional, one is titled a mock study, one calls itself an example record, and one copies Lilly's SURMOUNT-1 down to the protocol code. An NCT number is not evidence that a trial exists.

Matthew Kawa admitted forging lab certificates and was sentenced to 70 months on 30 July 2026. Six products sold as SARMs tested as testosterone. What a COA can prove, what it cannot, and the checks that hold.

On 18 September 2026 a federal jury convicted the owner of Pinned Aminos. The site said research use only and the labels said not for human consumption, while the sellers posted dosing directions in a private Facebook group. Prosecutors argued the disclaimer existed to mislead FDA, and the jury agreed.

Phenibut is not a federal controlled substance, but the FDA says it is not a lawful dietary ingredient, so it cannot be sold as a supplement. A handful of states restrict it, and it carries a real dependence and withdrawal risk.

Tianeptine is not FDA-approved and is sold gray-market as 'gas station heroin.' It is not a federal controlled substance yet, but FDA import-alerts it, warns consumers against it, and a growing list of states have banned or scheduled it.

2,087 public peptide lab results from six sources: median HPLC purity 99.86%, median fill 109.6% of label, and 47.6% of vials over 110%.

Federal agents searched an address listed for Apex Peptides on 23 Sep 2026. No charges by 10 Oct. Which Apex sites are live, and what to do about an order.

43% of vendor-claimed purity figures failed independent retesting. The gap concentrates in three patterns you can avoid before clicking buy.

The same operation now runs under two domains. The legacy site is still live, the new domain inherits the old contact infrastructure, and the Trustpilot review base was seeded via a promo-code review program. Here's the buyer-relevant breakdown.

Nexaph, EZ Peptides and Ameano show one SS-31 analysis on Janoshik tasks 163730-163732. Finnrick gives Nexaph a 60% pass rate. What the record shows.

CBP told the WSJ of 2,400+ drug-product seizures from Oct 2025 to Aug 2026. What a seizure notice means, and what a US warehouse does not change.

Reta One Labs, Beast Labs, Alpha One Aminos and Renova Peptides share 21 Kovera lot numbers: 22 tests issued as 87 certificates. What that means for you.

Chemyo, Eternal and Chameleon closed between 2026-09-08 and 09-27. What each notice said, what it didn't, and their last COAs on file.

Kovera's results check out; the company behind it is unverified. What reviews and Reddit say, which vendors use it, and how to check a KVR code yourself.

68 retatrutide and 48 tirzepatide Janoshik reports to 30 June 2026: median 110% and 113% of label, purity 99.8%, one vial under 90%.

FDA rejected the B12 'personalised' workaround on 2026-09-18 and has not finalised the 503B exclusion. What still qualifies under 503A.

FDA's 2026-09-18 Empower letter calls semaglutide/B12 'essentially copies'. The 503B exclusion is still pending. Where the legal channel stands.

All four retatrutide Phase 3 readouts on 12 mg: TRIUMPH-4 28.7% at 68 weeks (topline), TRIUMPH-1 25.0% (NEJM), TRIUMPH-2 18.8% (The Lancet), TRIUMPH-3 22.6% (topline).

29 research-peptide vendors have published 20 or more COAs through Kovera Labs. Ion Peptide leads at 105 records with zero flags. Two heavy publishers have concentrated quality issues. The full ranked table, deduped flag breakdown, and what to do with it as a buyer.

GLP-1 receptor agonists cause weight loss that is between 25% and 40% lean mass by default. Resistance training and protein intake shift that ratio. Here's the trial data and the protocol levers that actually move it.

FDA's August 2026 letters quoted GLP-1 S, GLP-2 TRZ, GLP-3 Reta and BIMORELIN by name. A code name stopped none of them. Decoder table.

Four structural drivers behind peptide-vendor alias clusters — payment-processor mortality, FDA enforcement, community detection lag, and upstream-supply-chain consolidation.

We re-ran every one of the 1,828 Kovera certificates we mirror. 57 had been revised under the same reference number, 20 of those moved a real value, and none crossed the 98% pass line. A COA number is not a stable citation.

Nine peptide vendors pitched us between 4 Sep and 7 Oct 2026. The top offer was 40% of every order. We are taking one, at 10%. The checks behind each call.

We applied a 10-signal hostname-aliasing check to 32 research-peptide vendor domains. Multiple confirmed alias clusters surfaced, including a smoking-gun shared Google Tag Manager ID linking three "different" peptide brands to one operator.

Some research-peptide brands aren't separate vendors — they're hostname aliases pointing at a shared backend. Here's how to detect the pattern in under sixty seconds, with a worked example from our own audit cohort.

When two 'different' peptide vendors cite the exact same Janoshik test URL for the same product batch, they're sourcing from the same upstream manufacturer. We documented this pattern between Summit Biotech and the Peptopia community-tracker batches — confirming Geneza Pharmaceuticals as the shared upstream.

SURMOUNT-5 (NEJM 2025, 751 adults, 72 weeks): tirzepatide cut weight 20.2% vs 13.7% on semaglutide. Dual GLP-1/GIP vs GLP-1 only, side effects and cost.

Both are GHRH analogs. Tesamorelin is FDA-approved as Egrifta; sermorelin's Geref approvals were withdrawn in 2009 for commercial reasons. How they differ.

UBT251 cut weight up to 19.7% at 24 weeks in a Chinese Phase 2; retatrutide cut 17.5% at 24 weeks. Our lab mirrors hold zero UBT251 test records.

Janoshik's GLP-1 test is $360; Finnrick's original COAs now need a $9.99/mo membership. Eight labs on price, identity method and how to verify.

EloraTZP lost 23.3% at 48 weeks in type 2 diabetes vs 20.8% for retatrutide at 80 weeks. Why that is not a head-to-head, and what eloralintide is.

Retatrutide 12 mg: 25.0% at 80 weeks (TRIUMPH-1). Tirzepatide 15 mg: 20.9% at 72 weeks (SURMOUNT-1). No head-to-head trial yet; type 2 diabetes data too.

Five 503A telehealth compounders audited under the same rubric - Trillium, Fifty410, Hims, Henry Meds, Mochi Health. Mochi leads on prescriber transparency (board-certified obesity-medicine physicians). Fifty410 leads on regulatory cleanliness. The full cohort comparison, scored.

They're not really "versus" - the two compounds work through different receptors and synergize. CJC-1295 hits the GHRH receptor; ipamorelin hits the ghrelin receptor. The stack is research-protocol canon. Here's the actual breakdown plus the comparison framing most buyers want.

Two repurposed drugs studied for longevity, two different mechanisms, two different evidence bases. Rapamycin has the strongest cross-species lifespan-extension data in pharmacology. Metformin has 60+ years of human safety data and the active TAME trial. The honest comparison.

Tesamorelin is a synthetic GHRH analog that prompts the pituitary to release endogenous GH. HGH is the hormone itself. Here's what the literature says about both, why a growing community is switching from one to the other, and what to consider before you do.

Retatrutide price per month: the 12 mg TRIUMPH arm used 48 mg per 4 weeks, $168 to $626 at 21 October 2026 gray-market prices (median $312).

No peptide is approved to treat insomnia. The best human sleep data belong to GHRH, the hormone sermorelin is cut from, which raised deep sleep in sleep-lab studies of 7 to 23 men. DSIP's best trial was negative. Ipamorelin, CJC-1295 and Selank have no sleep study at all.

The Wolverine stack is BPC-157 plus TB-500. No human trial has tested the pair. Of 81 blend lab results we checked, 1 failed on fill.

Nausea hit 28% on 12 mg retatrutide vs 8% on placebo in TRIUMPH-2. Diarrhea, dysesthesia, hypotension and dropout rates by dose, from The Lancet.

TRIUMPH-2 stepped retatrutide 2, 4, 6, 9, then 12 mg every 4 weeks. Week-by-week chart with syringe units for 10 and 20 mg vials.

A research read on the peptides currently studied for longevity outcomes - rapamycin, NAD+, MOTS-c, GHK-Cu, Klotho, epitalon, GHRH analogs, and the rest. Which have human evidence, which have only model-organism data, and what each actually does at the mechanism level.

KLOW is a four-component peptide stack growing fast in research-protocol discussion. Here's the literature read - what each compound does, what the mechanism overlap argues, and what's actually been studied as a combination.

Scan the QR or enter the test ID on Janoshik's Verify page, then match compound, purity and sample date at verify.janoshik.com. No test ID, no check.

18.50 EU/mg on a 10 mg vial is 185 EU per vial. How to convert endotoxin units, where USP <85> limits come from, and why a lab's Pass depends on the spec.

Vanguard's A2LA scope lists no peptide test. For 42 Core Peptides reports, the shop's PDF drops the quantity line the lab's own copy prints.

FDA's 2026-08-24 letters name 'GLP-3 RT', 'GLP-3R' and 'GLP-3 Reta' as retatrutide. Alias table with COA purity per code name.

Reddit testers report reta vials that tested as semaglutide or held no analyte. How to tell a fake or degraded vial from a slow response.

All five FDA peptide letters of 2026-08-24 cite bac water; four list it as an unapproved drug. Shelf life after opening, sterile water, supply status.

10 mg peptide plus 2 mL bac water gives 5 mg/mL, so 250 mcg is 5 units on a U-100 syringe. Printable chart and worked vial examples.

BAC water and syringe math for 5, 10 and 20 mg retatrutide vials, mapped to the TRIUMPH-2 dose steps. Research only, not human-use guidance.

Cloudiness in a reconstituted peptide vial is one of the most common buyer panics. It's sometimes harmless aggregation, sometimes contamination, sometimes solvent-induced precipitation. Here's how to tell which one.

Eight failure modes, ranked by how often they appear in public Janoshik data and how hard they are for a buyer to catch before ordering.

Retatrutide is not approved. Lilly's expanded access program is the only legal route, and Lilly sued six sellers on 2026-08-12. What that means for buyers.